

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

GREAT POINT PARTNERS LLC  
Form SC 13D/A  
June 19, 2007

OMB APPROVAL	
OMB Number: 3235-0145	
Expires: February 28, 2009	
Estimated average burden	
hours per response	14.5

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D  
UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 1)\*

GENTIUM SpA

(Name of Issuer)

AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE ORDINARY SHARE

(Title of Class of Securities)

37250B14

(CUSIP Number)

DR. JEFFREY R. JAY, MD  
GREAT POINT PARTNERS, LLC  
165 MASON STREET, 3RD FLOOR  
GREENWICH, CT 06830.  
(203) 971-3300

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

JUNE 15, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. |  |

NOTE: Schedule filed in paper format shall include a signed original and five

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

-----  
CUSIP No. 37250B14  
-----

=====  
1 Names of Reporting Persons.

Great Point Partners, LLC

I.R.S. Identification Nos. of above persons (entities only).

37-1475292  
-----

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)   
-----

3 SEC Use Only  
-----

4 Source of Funds (See Instructions) AF  
-----

5 Check if Disclosure of Legal Proceedings is Required Pursuant to  
Items 2(d) or 2(e)

6 Citizenship or Place of Organization Delaware  
-----

Number of Shares	7	Sole Voting Power	-0-
Beneficially Owned by	8	Shared Voting Power	425,532
Each Reporting Person With	9	Sole Dispositive Power	-0-
	10	Shared Dispositive Power	425,532

-----

11 Aggregate Amount Beneficially Owned by Each Reporting Person 425,532  
-----

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

(See Instructions) |\_  
-----

13 Percent of Class Represented by Amount in Row (11) 2.92%  
-----

14 Type of Reporting Person (See Instructions)  
OO  
=====

2

-----  
CUSIP No. 37250B14  
-----

=====

1 Names of Reporting Persons.

Dr. Jeffrey R. Jay, M.D.

I.R.S. Identification Nos. of above persons (entities only).  
-----

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a) |\_  
-----

(b) |\_  
-----

3 SEC Use Only  
-----

4 Source of Funds (See Instructions) AF  
-----

5 Check if Disclosure of Legal Proceedings is Required Pursuant to  
Items 2(d) or 2(e) |\_  
-----

6 Citizenship or Place of Organization United States  
-----

Number of Shares	7	Sole Voting Power	-0-
Beneficially Owned by	8	Shared Voting Power	425,532
Each Reporting Person With	9	Sole Dispositive Power	-0-
	10	Shared Dispositive Power	425,532

-----

11 Aggregate Amount Beneficially Owned by Each Reporting Person 425,532  
-----

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
(See Instructions) |\_  
-----

13 Percent of Class Represented by Amount in Row (11) 2.92%  
-----

14 Type of Reporting Person (See Instructions)  
IN  
=====

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

3

-----  
CUSIP No. 37250B14  
-----

=====

1 Names of Reporting Persons.

Biomedical Value Fund, L.P.

I.R.S. Identification Nos. of above persons (entities only).

20-0308288

-----

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

-----

3 SEC Use Only

-----

4 Source of Funds (See Instructions) PF

-----

5 Check if Disclosure of Legal Proceedings is Required Pursuant to  
Items 2(d) or 2(e)

-----

6 Citizenship or Place of Organization Delaware

-----

Number of Shares	7	Sole Voting Power	-0-
Beneficially Owned by	8	Shared Voting Power	212,766
Each Reporting Person With	9	Sole Dispositive Power	-0-
	10	Shared Dispositive Power	212,766

-----

11 Aggregate Amount Beneficially Owned by Each Reporting Person 212,766

-----

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
(See Instructions)

-----

13 Percent of Class Represented by Amount in Row (11) 1.46%

-----

14 Type of Reporting Person (See Instructions)  
PN

=====

4

-----  
CUSIP No. 37250B14  
-----

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

1 Names of Reporting Persons.

Biomedical Offshore Value Fund, Ltd.

I.R.S. Identification Nos. of above persons (entities only).

N/A

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3 SEC Use Only

4 Source of Funds (See Instructions) PF

5 Check if Disclosure of Legal Proceedings is Required Pursuant to  
Items 2(d) or 2(e)

6 Citizenship or Place of Organization Delaware

Number of Shares	7	Sole Voting Power	-0-
Beneficially Owned by	8	Shared Voting Power	212,766
Each Reporting Person With	9	Sole Dispositive Power	-0-
	10	Shared Dispositive Power	212,766

11 Aggregate Amount Beneficially Owned by Each Reporting Person 212,766

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
(See Instructions)

13 Percent of Class Represented by Amount in Row (11) 1.46%

14 Type of Reporting Person (See Instructions)  
00

This Amendment No. 1 to Schedule 13D (this "Amendment") is filed by the undersigned to amend the Statement on Schedule 13D, filed by the undersigned on October 24, 2005 (the "Original Filing"). Unless otherwise indicated, all capitalized terms shall have the same meaning as provided in the Original Filing. Any reference to "this Schedule 13D" in the Original Filing or in this Amendment shall refer to the Original Filing as amended by this Amendment.

ITEM 1. SECURITY AND ISSUER

The title and class of equity securities to which this statement on Schedule D relates is American Depositary Shares ("ADS"), each representing one ordinary share of Gentium SpA (the "Issuer"). The ADSs have been issued pursuant to a Deposit Agreement dated as of June 15, 2005, among the Issuer, the Bank of

## Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

New York, as Depositary, and the owners from time to time of ADSs issued thereunder.

The name and address of the principal executive offices of the Issuer is Gentium SpA, Piazza XX Settembre 2, 22079 ViVa Guardia, Como Italy.

### ITEM 2. IDENTITY AND BACKGROUND

Item 2 is hereby amended to change the address of Biomedical Value Fund, L.P. ("BMVF"), Great Point Partners LLC ("Great Point"), and Dr. Jeffrey R. Jay ("Dr. Jay"), from 2 Pickwick Plaza, Suite 450, Greenwich, CT, 06830 (as originally filed on October 24, 2005), to the current principal office at 165 Mason Street, 3rd Floor, Greenwich, CT, 06830.

### ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Not applicable.

### ITEM 4. PURPOSE OF TRANSACTION

Between June 13th and 15th, 2007, each of BMVF and BOVF sold all of the ADSs owned by them. See Item 5 for continuing beneficial ownership.

### ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 is hereby amended and restated as follows:

(a) through (b)

BMVF owns warrants to purchase 212,766 ADSs. Such securities, in the aggregate, constitute 1.46% percent of the outstanding share capital of the Issuer, computed in accordance with Rule 13d-3. BMVF shares dispositive power over the warrants to purchase ADSs owned by it and, in the event of the exercise of such warrants, would share voting power with respect to the ADSs for which such warrants are exercisable. BMVF disclaims beneficial ownership of any securities owned by BOVF. See Item 2.

6

BOVF owns warrants to purchase 212,766 ADSs. Such securities, in the aggregate, constitute 1.46% percent of the outstanding share capital of the Issuer, computed in accordance with Rule 13d-3. BOVF shares dispositive power over the warrants to purchase ADSs owned by it and, in the event of the exercise of such warrants, would share voting power with respect to the ADSs for which such warrants are exercisable. BOVF disclaims beneficial ownership of any securities owned by BMVF. See Item 2.

The warrants to purchase ADSs will be issued only if the issuance thereof, including the ordinary shares of the Issuer underlying the ADSs, are authorized at a shareholders' meeting of the Issuer.

Great Point is the investment manager of each of BMVF and BOVF, and by virtue of such status has shared voting and investment power with respect to securities owned and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Dr. Jay, as senior managing member of Great Point, has shared voting and investment power with respect to securities owned

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Great Point and Dr. Jay disclaim beneficial ownership of the shares of Common stock held by BMVF and BOVF, except to the extent of any pecuniary interest, and this Schedule 13D shall not be deemed to be an admission that they are the beneficial owners of such securities.

(c) From the period between June 13, 2007 and June 15, 2007 BMVF sold 531,915 ADSs held by it and BOVF sold 531,915 ADSs held by it.

(d) Not applicable.

(e) Each of the persons referred to in Item 2 ceased to be the beneficial owner of more than five percent of any class of securities of the Issuer on June 15, 2007.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

Not applicable.

7

ITEM 7. MATERIALS TO BE FILED AS EXHIBITS

EXHIBIT A: Joint Filing Agreement, dated as of October 21, 2005 (as filed on the Schedule 13D dated as of October 24, 2005, and incorporated herein by reference).

8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 19, 2007

Biomedical Value Fund, L.P.

By: Great Point GP, LLC, its general partner

By: /S/ DR. JEFFREY R. JAY

-----  
Name: Dr. Jeffrey R. Jay  
Title: Senior Managing Member

Edgar Filing: GREAT POINT PARTNERS LLC - Form SC 13D/A

Biomedical Offshore Value Fund, Ltd.

By: Great Point GP, LLC, its investment  
manager

By: /S/ DR. JEFFREY R. JAY

-----  
Name: Dr. Jeffrey R. Jay  
Title: Senior Managing Member

Great Point Partners, LLC

By: /S/ DR. JEFFREY R. JAY

-----  
Name: Dr. Jeffrey R. Jay  
Title: Senior Managing Member

/S/ DR. JEFFREY R. JAY

-----  
Dr. Jeffrey R. Jay, individually